Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FTC Focus On Pay-For-Delay Deals Continues; Endo Agrees To 10-Year Abstention

Executive Summary

In addition to settling with Endo, FTC refiles charges against Watson (now Teva), Allergan and Impax involving Lidoderm and Opana ER patent litigation settlements.

Advertisement

Related Content

Pay-For-Delay Settlements Decline In Wake Of Supreme Court Ruling
Teva Settles 16-Year Cipro Pay-For-Delay Litigation For $225M; Will Focus Shift To Pricing Deals?
Generic Price Fixing Probe: First Charges Unsealed, More May Come Before Inauguration Day
Patent Settlements Stir Supreme Court Interest During Slow Term For Pharma Cases
FTC v. Endo: Does No-Authorized Generic Agreement Meet Supreme Court Pay-For-Delay Test?
Teva’s Pay-For-Delay Settlement Restricts Brand-Generic Deals
Pay-For-Delay Deals May Be Smaller After Supreme Court Okays FTC Suits

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS119901

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel